Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by bluemoons20on Nov 25, 2022 9:40am
67 Views
Post# 35127838

RE:RE:RE:RE:Arbitration

RE:RE:RE:RE:Arbitration Agree  entirely.

Guess I  missread  or read the  rules too quickly.  Looked like it said  once announced  party has 30  days  , respondent then 30  days  and then  first party has another30 days to respond   and  then it  goes to hearing  with  45 days to select  arbitrator  (  which  is concurrent to  original 90  days.

Unless the  arbitrator has a huge  backlog  for time to have the hearing,  this should have been long  over  even with the 60  days  to  render award??

Guess  we have to  wait.  But seems every day you wait the  shares price  drops.  I  just fear  we will be  bought out  for  5  cents.  and the new owner will reap the  rewards.  Which is totally  unfair  for longterm  shareholders

GLTA


<< Previous
Bullboard Posts
Next >>